|
|
Article: Acadia Pharmaceuticals Inc.
- Article from:
- San Diego Business Journal
- Article date:
- February 13, 2006
CopyrightCOPYRIGHT 2006 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ACADIA PHARMACEUTICALS INC.
NASDAQ--ACAD
Acadia Pharmaceuticals Inc. is a bio-pharmaceutical company focused on
the discovery, development and commercialization of small molecule
drugs for the treatment of central nervous system disorders. In 2004,
Acadia had four drug programs in clinical development and several
additional programs in preclinical and discovery stages. The company's
three Phase II clinical programs are ACP-103 for treatment-induced
dysfunctions in Parkinson's disease, ACP-103 as an adjunctive therapy
for schizophrenia, and ACP-104 for the treatment of schizophrenia.
Acadia has retained worldwide commercialization rights for these
programs. The ...